Item 16. FORM 10-K SUMMARY

3K characters. Original on sec.gov · Markdown

Item 16. FORM 10-K SUMMARY

None.


113			\| 2024 Form 10-K

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, AbbVie Inc. has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


AbbVie Inc.
By:	/s/ ROBERT A. MICHAEL
	Name:	Robert A. Michael
	Title:	Chief Executive Officer and Director
Date:	February 14, 2025

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of AbbVie Inc. on February 14, 2025 in the capacities indicated below.


/s/ ROBERT A. MICHAEL						/s/ SCOTT T. REENTS
Robert A. Michael Chief Executive Officer and Director (Principal Executive Officer)						Scott T. Reents Executive Vice President, Chief Financial Officer (Principal Financial Officer)

/s/ KEVIN K. BUCKBEE						/s/ RICHARD A. GONZALEZ
Kevin K. Buckbee Senior Vice President, Controller (Principal Accounting Officer)						Richard A. Gonzalez Executive Chairman of the Board and Retired Chief Executive Officer

/s/ ROBERT J. ALPERN, M.D.						/s/ ROXANNE S. AUSTIN
Robert J. Alpern, M.D. Director of AbbVie Inc.						Roxanne S. Austin Director of AbbVie Inc.

/s/ WILLIAM H.L. BURNSIDE						/s/ JENNIFER L. DAVIS
William H.L. Burnside Director of AbbVie Inc.						Jennifer L. Davis Director of AbbVie Inc.

/s/ THOMAS C. FREYMAN						/s/ BRETT J. HART
Thomas C. Freyman Director of AbbVie Inc.						Brett J. Hart Director of AbbVie Inc.

/s/ MELODY B. MEYER						/s/ SUSAN E. QUAGGIN, M.D.
Melody B. Meyer Director of AbbVie Inc.						Susan E. Quaggin, M.D. Director of AbbVie Inc.

/s/ EDWARD J. RAPP						/s/ REBECCA B. ROBERTS
Edward J. Rapp Director of AbbVie Inc.						Rebecca B. Roberts Director of AbbVie Inc.

/s/ GLENN F. TILTON						/s/ FREDERICK H. WADDELL
Glenn F. Tilton Director of AbbVie Inc.						Frederick H. Waddell Director of AbbVie Inc.


						2024 Form 10-K \|			114

Previous: Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES